Close Menu

NEW YORK – Bio-Techne said on Thursday that its fiscal year 2021 first quarter revenues rose 11 percent year over year, driven in part by growth in its Diagnostics and Genomics segment.

For the three months ended Sept. 30, the firm reported revenues of $204.2 million compared to $183.2 million in Q1 2020, and beating analysts' average estimate of $185.0 million. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.